Europe:+32-2-535-7543
Asia: +65-6223-2436
Int'l: +1-860-674-8796
US: +1-866-353-3335
  • Japanese
  • Korean
  • Chinese
Cover Image

World Vaccines Industry and Market 2015-2025

Vaccines and their technology - your guide to developments, opportunities and revenues

See what the future holds for vaccines. Visiongain's updated report lets you assess forecasted sales at overall world market, submarket, product and national level to 2025.

Make sure you understand trends, R&D, opportunities and prospects there, in human medicine. That way you can help your research, analysis and decisions. For those technologies, discover in our study what's likely to happen. And find what gains are possible.

Vaccines still hold great technological, medical and commercial potential. See why. So please read on to explore that industry and hear what its future market could be worth.

Forecasts from 2015 to 2025 and other analyses showing you commercial prospects

Besides revenue forecasting to 2025, our new work gives you historical data, recent results, growth rates and market shares. There you find business outlooks and developments (R&D).

You also get 50 tables, 49 charts and two interviews, with other opinion. That study includes our discussions with GSK and BiondVax Pharmaceuticals.

Gains through understanding the vaccines sector - find advantages for your work

Leaders hold knowledge. So hear what's happening for development, production and sales of those preventative medicines. There, from 2015, you see where needs and money exist.

And avoid struggles to gain business information. Instead use our predictions for vaccination to expand your business and help your influence. That way, benefit your authority and stay ahead.

Discover how you and your organisation can gain. The following sections reveal what you get in that new investigation.

Revenues for the world vaccines market and submarkets

What's that industry's potential? What're the secrets of its progress? Discover in our report overall world revenue to 2025. Also find individual forecasts for main submarkets at world level:

  • Paediatric vaccines
  • Adult vaccines.

How will sales rise? See, then, which product classes can generate most revenue. There you assess prospects for commercial expansion. Discover now the money-earning potential.

Explore the market for vaccinations by brand too.

Forecasts and discussions for leading marketed products

How will leading brands perform to 2025 at world level? Our work shows you 10 individual revenue forecasts to 2025 for top products:

  • Prevnar group
  • Gardasil
  • PENTAct-HIB
  • Pediarix
  • Varivax/M-M-R II/ProQuad.

And also for these agents:

  • Fluzone/Vaxigrip
  • Hepatitis group, GSK
  • Zostavax
  • Pneumovax-23
  • RotaTeq.

There you assess potentials, seeing activities, results and outlooks. You discover what's happening, understanding trends, competition and sales prospects. Assess the future, then, including prospects for newer agents.

Newer vaccines and products in development - how will leading candidates perform?

Also see how newer agents, especially those in development and awaiting launch, can perform. For these 11 medicines, see revenues to 2025:

  • Zoster and Malaria vaccines (GSK)
  • 9-valent HPV agents (Merck)
  • Hexavalent paediatric vaccines (Sanofi)
  • Dengue fever products (Sanofi)
  • Trumenba vaccines (Pfizer).

And get forecasts for these treatments:

  • C. difficile and S. aureus vaccines (Pfizer)
  • Ebola vaccines (Johnson & Johnson)
  • Dengue fever vaccines (Takeda)
  • Universal influenza vaccines (BiondVax).

There you assess the future of that industry's developments, finding sales gains possible.

Our study also divides its overarching world forecast into geographical regions.

Healthcare in national markets - what outlooks for sales of those medicines?

Progress worldwide in vaccines and healthcare will expand vaccination. You hear about the best revenue prospects for those preventative medicines, getting feel for national prospects.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:

  • United States (US)
  • Japan
  • European Union (grouped forecast)
  • Germany, France, United Kingdom (UK), Italy and Spain (EU5 countries)
  • Brazil, Russia, India and China (BRIC group).

There you assess developed and developing countries for revenues and potential sales growth. Our work explains. See effects of existing and future prophylactic medicines.

Research and development - explore trends, possibilities and innovations

Our study discusses R&D for immune system modifiers, finding possibilities for technological and commercial advances.

In particular, our report discusses these medical technologies:

  • Influenza vaccines
  • Prophylactic treatments, including those for meningitis, pneumonia, TB, diphtheria, pertussis, tetanus and rotaviruses
  • Protectors against Dengue virus
  • Vaccines for HIV, malaria and bacteria
  • Prophylaxis in oncology - cancer vaccines - including agents for prostate, pancreatic and lung cancers.

Developments in those immunological treatments hold strength, variety and promise. See what's possible there for large pharmaceutical companies and biopharma specialists.

Our study explains progress in human prophylaxis, discussing issues to help your work.

Events affecting developers, producers and sellers of vaccines

The report explains forces affecting that industry and market from 2015, including these issues:

  • Importance of those products to the pharmaceutical industry
  • Immunisation needs and practices in the US
  • Medical demands vying with budgetary restraints in Europe
  • Rising need in emerging countries and under-developed regions
  • Delivery systems, adjuvants and other innovations.

There you explore political, economic, social and technological questions, investigating outlooks for business. Examine forces stimulating and restraining that industry and market.

You discover what their present and future hold.

Companies and overall 2019 market value - what revenue possible?

What happens next? Our report predicts the overall world market for vaccines will reach $56.38bn worldwide in 2019, with strong further expansion to 2025.

Find how high its revenues can go. Discover in our work what's possible for prophylactic medicine and see which companies hold greatest potential.

In particular, you explore these organisations:

  • GlaxoSmithKline (GSK)
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • Takeda
  • Merck & Co.

From 2015 to 2025 vaccines will benefit patients, payers and companies. Our analysis predicts technological and commercial advances there. Stay ahead by using that work.

Data found nowhere else - explore vaccine development, production and sales

In particular, our new investigation gives you these advantages for your research, analyses and decisions:

  • Revenues to 2025 for vaccines at world level and for two main submarkets - assess prospects for investments, marketing and sales
  • Predictions for 21 products to 2025 - discover revenue potentials of leading marketed vaccines and agents in development, awaiting launch
  • Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for potential revenues
  • Prospects for established competitors, rising companies and new entrants - explore products, R&D, opinions from interviews and outlooks for success.

World Vaccines Industry and Market 2015-2025 provides independent research and analysis. There you get competitive intelligence found only in our work, finding where the money lies. Explore progress and possibilities.

With that report, by in-house UK-based analysts, you're less likely to miss knowledge and opportunity. Also find there how you could save time and gain more recognition for insight.

Trying that study now lets you discover trends, predictions and sales opportunities

Our investigation is for everyone analysing preventative medicines and related biotechnology. There you discover predictions and discussions for vaccines. Avoid missing out. Instead please get that new report here now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Why You Should Read This Report
  • 1.2. How This Report Delivers
  • 1.3. Main Questions Answered by this Analysis
  • 1.4. Who is this Study for?
  • 1.5. Methods of Research and Analysis
  • 1.6. Frequently Asked Questions (FAQs)
  • 1.7. Some Associated Reports
  • 1.8. About Visiongain

2. Introduction to the World Human Vaccines Market

  • 2.1. Human World Vaccines - Aiming for Global Disease Prevention
  • 2.2. Vaccine Technology
    • 2.2.1. Inactivated Vaccines
    • 2.2.2. Live Attenuated Vaccines
    • 2.2.3. Conjugate Vaccines
    • 2.2.4. Recombinant Vector Vaccines
  • 2.3. Human World Vaccines - Market Segmentation
  • 2.4. Paediatric Vaccines
  • 2.5. Adolescent Vaccines
  • 2.6. Adult Vaccines
  • 2.7. Elderly Vaccines
  • 2.8. Blurred Lines

3. World Vaccine Market Outlook, 2015-2025

  • 3.1. World Vaccine Market, 2014
  • 3.2. World Vaccine Market Forecast: 2015-2025
  • 3.3. World Vaccine Market: Industry Trends, 2015-2025
    • 3.3.1. Demand-Side Trends
    • 3.3.2. Supply-Side Trends
    • 3.3.3. Funding Trends
    • 3.3.4. Decreasing Number of Lower Income Countries (LICs)

4. World Vaccine Submarkets: Prospects, 2015-2025

  • 4.1. Paediatric Vaccines
    • 4.1.1. Paediatric Vaccine Forecast: 2015-2025
    • 4.1.2. Paediatric Vaccine Trends
      • 4.1.2.1. Novel Delivery
      • 4.1.2.2. Fear Factor
      • 4.1.2.3. Novel Vectors
    • 4.1.3. Paediatric Vaccine R&D Pipeline
  • 4.2. Adult Vaccines
    • 4.2.1. Adult Vaccine Forecast: 2015-2025
    • 4.2.2. Adult Vaccine Trends
      • 4.2.2.1. Treat the Untreatable
      • 4.2.2.2. 'Tis the Season
      • 4.2.2.3. Exotic Killers
    • 4.2.3. Adult Vaccine R&D Pipeline

5. Leading Vaccines: Revenue Predictions to 2025

  • 5.1. Prevnar-13 - Pfizer: Sales Forecasting and Discussions, 2014-2025
  • 5.2. Gardasil - Merck: Sales Forecasting and Discussions, 2014-2025
  • 5.3. PENTAct-HIB - Sanofi: Sales Forecasting and Discussions, 2014-2025
  • 5.4. Pediarix - GSK: Sales Forecasting and Discussions, 2014-2025
  • 5.5. Varivax/M-M-R II/ProQuad - Merck: Sales Forecasting and Discussions, 2014-2025
  • 5.6. Fluzone/Vaxigrip - Sanofi: Sales Forecasting and Discussions, 2014-2025
  • 5.7. Hepatitis Vaccine Franchise - GSK: Sales Forecasting and Discussions, 2014-2025
  • 5.8. Zostavax - Merck: Sales Forecasting and Discussions, 2014-2025
  • 5.9. Pneumovax 23-Merck: Sales Forecasting and Discussions, 2014-2025
  • 5.10. RotaTeq - Merck: Sales Forecasting and Discussions, 2014-2025

6. Leading National Vaccines Markets: 2015-2025

  • 6.1. Human Vaccines: Leading Markets, 2013, 2019 and 2025
  • 6.2. The US Vaccine Market: 2015-2025
    • 6.2.1. The US Vaccine Market: 2014
    • 6.2.2. The US Vaccine Market Forecast: 2015-2025
    • 6.2.3. Obama Healthcare Reform - Benefits for Vaccine Sales
  • 6.3. The Japanese Vaccine Market: 2015-2025
    • 6.3.1. The Japanese Vaccine Market: 2014
    • 6.3.2. The Japanese Vaccine Market Forecast: 2015-2025
    • 6.3.3. Breaking Barriers
  • 6.4. European Union (EU) Vaccine Market: 2015-2025
    • 6.4.1. EU Vaccine Market: 2014
    • 6.4.2. EU Vaccines Market Forecast: 2015-2025
    • 6.4.3. Europe's Crises
  • 6.5. The German Vaccine Market: 2015-2025
    • 6.5.1. The German Vaccine Market: 2014
    • 6.5.2. The German Vaccine Market Forecast: 2015-2025
    • 6.5.3. Pricey Business
  • 6.6. The French Vaccine Market: 2015-2025
    • 6.6.1. The French Vaccine Market: 2014
    • 6.6.2. The French Vaccine Market Forecast: 2015-2025
    • 6.6.3. French Healthcare System - Events, Policies and Effects
  • 6.7. The UK Vaccine Market: 2015-2025
    • 6.7.1. The UK Vaccine Market: 2014
    • 6.7.2. The UK Vaccine Market: 2015-2025
  • 6.8. The Italian Vaccine Market: 2015-2025
    • 6.8.1. The Italian Vaccine Market: 2014
    • 6.8.2. The Italian Vaccine Market Forecast: 2015-2025
    • 6.8.3. Crumbling Foundation - Challenges in Public Healthcare
  • 6.9. The Spanish Vaccine Market: 2015-2025
    • 6.9.1. The Spanish Vaccine Market: 2014
    • 6.9.2. The Spanish Vaccine Market Forecast: 2015-2025
    • 6.9.3. District Rules - Economic Challenges
  • 6.10. The Brazilian Vaccine Market: 2015-2025
    • 6.10.1. The Brazilian Vaccine Market: 2014
    • 6.10.2. The Brazilian Vaccine Market Forecast: 2015-2025
    • 6.10.3. Dengue Focus
  • 6.11. The Russian Vaccine Market: 2015-2025
    • 6.11.1. The Russian Market: 2014
    • 6.11.2. The Russian Vaccine Market Forecast: 2015-2025
    • 6.11.3. Power of the State
  • 6.12. The Indian Vaccine Market: 2015-2025
    • 6.12.1. The Indian Vaccine Market: 2014
    • 6.12.2. The Indian Vaccine Market Forecast: 2015-2025
    • 6.12.3. Slow Adoption of Vaccines - How Much Progress Possible?
  • 6.13. The Chinese Vaccine Market: 2015-2025
    • 6.13.1. The Chinese Vaccine Market: 2014
    • 6.13.2. The Chinese Vaccine Market Forecast: 2015-2025
    • 6.13.3. Domestic Vaccine Producers and High National Demand

7. Leading Manufacturers of Vaccines for Human Use

  • 7.1. GlaxoSmithKline (GSK)
    • 7.1.1. GSK Vaccine Performance
    • 7.1.2. GSK Developments
      • 7.1.2.1. Mergers and Acquisitions
      • 7.1.2.2. GSK Vaccine Pipeline
  • 7.2. Merck & Co.
    • 7.2.1. Merck Vaccine Performance
    • 7.2.2. Merck Developments
      • 7.2.2.1. Merck Market Movements
      • 7.2.2.2. Collaborations
      • 7.2.2.3. Merck Pipeline
  • 7.3. Sanofi
    • 7.3.1. Sanofi Vaccine Performance
    • 7.3.2. Sanofi Developments
      • 7.3.2.1. Mergers & Acquisitions
      • 7.3.2.2. Sanofi Vaccine Pipeline
  • 7.4. Pfizer
    • 7.4.1. Pfizer Vaccine Performance
    • 7.4.2. Pfizer Developments
      • 7.4.2.1. Pfizer Mergers & Acquisitions
      • 7.4.2.2. Pfizer Pipeline
  • 7.5. Johnson & Johnson
  • 7.6. AstraZeneca
  • 7.7. Other Contenders

8. Qualitative Analysis of the World Vaccines Industry and Market: 2015

  • 8.1. SWOT Analysis of the World Vaccines Industry and Market: 2015-2025
    • 8.1.1. Strengths
      • 8.1.1.1. Ageing Population
      • 8.1.1.2. Strong Research and Development Pipeline
      • 8.1.1.3. Viral Disease Prevention is Crucial
      • 8.1.1.4. Continuing Product Development
    • 8.1.2. Weaknesses
      • 8.1.2.1. R&D Costs
      • 8.1.2.2. Barriers to Market Entry
    • 8.1.3. Opportunities
      • 8.1.3.1. Technological Advances to Protect People from Diseases
      • 8.1.3.2. Vaccine Delivery - Innovations and Opportunities for Improvements
      • 8.1.3.3. Adult Vaccines - High Need
    • 8.1.4. Threats
      • 8.1.4.1. Regulatory Scrutiny Daunting for Some Developers and Marketers
      • 8.1.4.2. Productivity Gap
  • 8.2. STEP Analysis of the World Vaccines Industry and Market: 2015
    • 8.2.1. Social Factors
      • 8.2.1.1. Healthcare Benefits from those Products
      • 8.2.1.2. Public Fears - Resistance from Some Quarters
    • 8.2.2. Technological Forces
      • 8.2.2.1. Technological Improvements to Sustain that Industry's Success
    • 8.2.3. Economic Factors
      • 8.2.3.1. Costs of Research and Development and Need for Large Vaccine Markets
      • 8.2.3.2. Rising Demand from Less Economically Developed Countries
    • 8.2.4. Political Forces
      • 8.2.4.1. Governmental Influence Shaping the Vaccines Market

9. Opinions from Our Industry Survey

  • 9.1. Progress Statement from GlaxoSmithKline, January 2015
    • 9.1.1. GSK Ebola Vaccine Candidate - Results and Plans
  • 9.2. Interview with Dr Louis J. Picker, Oregon Health and Science University
    • 9.2.1. Challenges of DNA/Ad Vector Vaccines
    • 9.2.2. Broadly Neutralising Antibodies for HIV
    • 9.2.3. A Third Way? The T-Cell Vaccine Approach
    • 9.2.4. Combinations and Other Strategies for HIV
    • 9.2.5. Getting to the Clinic with Therapeutic and Prophylactic HIV Vaccines
  • 9.3. Interview with Tamar Ben-Yedidia, PhD, Chief Scientific Officer, and Tanya Gottlieb, PhD, Business Development, BiondVax Pharmaceuticals
    • 9.3.1. Progress of BiondVax's Candidate Vaccine
    • 9.3.2. Trialling the Vaccine as a Primer
    • 9.3.3. Assays for Universal Vaccine Effectiveness
    • 9.3.4. Key Differentiators for BiondVax's Candidate

10. Conclusions

  • 10.1. Serving Needs in Chronic Diseases - Vital Protective Agents
  • 10.2. The Rise of Japan as a Vaccines Market
  • 10.3. The US to Lose its Dominance in Vaccine Sales?
  • 10.4. Emerging National Markets to Increase in Commercial Prominence
  • 10.5. Strong, Promising Research and Development
  • 10.6. Concluding Remarks

List of Tables

  • Table 1.1: Selected National Human Vaccines Markets: Revenue ($bn), Annual Growth (%), CAGR (%), 2013-2019
  • Table 1.2: Selected National Human Vaccines Markets: Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2025
  • Table 3.1: Overall World Human Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 4.1: Human Vaccines Sub-Markets: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2013-2025
  • Table 4.2: The Paediatric Human Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 4.3: The Adult Human Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.1: Human Vaccines Leading Vaccines: Revenues ($bn), 2013
  • Table 5.2: Prevnar Revenue ($bn), 2010-2013
  • Table 5.3: Prevnar Family: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.4: Gardasil Revenue ($bn), 2011-2013
  • Table 5.5: Gardasil: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.6: PENTAct-HIB Revenue ($bn), 2012-2013
  • Table 5.7: PENTAct-HIB: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.8: Pediarix Revenue ($bn), 2012-2013
  • Table 5.9: Pediarix: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.10: Varivax/M-M-R II/ ProQuad Revenue ($bn), 2011-2013
  • Table 5.11: Varivax/M-M-R II/ProQuad: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.12: Fluzone/Vaxigrip Revenue ($bn), 2012-2013
  • Table 5.13: Fluzone/Vaxigrip: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.14: Hepatitis Family, GSK Revenue ($bn), 2012-2013
  • Table 5.15: Hepatitis Family, GSK: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.16: Zostavax Revenue ($bn), 2011-2013
  • Table 5.17: Zostavax: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.18: Pneumovax-23 Revenue ($bn), 2011-2013
  • Table 5.19: Pneumovax-23: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 5.20: RotaTeq Revenue ($bn), 2011-2013
  • Table 5.21: RotaTeq: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2014-2025
  • Table 6.1: Human Vaccines Market Revenues ($bn) and Market Shares (%) by Leading Country, 2013, 2019 and 2025
  • Table 6.2: The US Human Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.3: The Japanese Human Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.4: The EU Human Vaccines Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.5: The German Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.6: The French Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.7: The UK Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.8: The Italian Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.9: The Spanish Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.10: The Brazilian Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.11: The Russian Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.12: The Indian Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 6.13: The Chinese Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2014-2025
  • Table 7.1: GSK Regional Vaccines Breakdown ($bn), 2013
  • Table 7.2: GSK Zoster Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2025
  • Table 7.3: GSK Malaria Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2025
  • Table 7.4: Merck Nine-Valent HPV Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2025
  • Table 7.5: Sanofi Hexavalent Paediatric Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 7.6: Sanofi Dengue Fever Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2016-2025
  • Table 7.7: Pfizer Trumenba Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 7.8: Pfizer C. difficile Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2025
  • Table 7.9: Pfizer S. aureus Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2025
  • Table 7.10: Johnson & Johnson Ebola Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 7.11: Takeda Dengue Fever Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2017-2025
  • Table 7.12: BiondVax Universal Influenza Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025

List of Figures

  • Figure 1.1: Human Vaccines Market Segmentation, 2015-2025
  • Figure 3.1: Human Vaccines: Leading National Market Shares (%), 2013
  • Figure 3.2: Human Vaccines: Leading National Market Shares (%), 2014
  • Figure 3.3: Human Vaccines: World-Market Segmentation (%), 2014
  • Figure 3.4: Global Human Vaccines Market: Drivers and Restraints, 2015-2025
  • Figure 4.1: Human Vaccines: Main Submarket Segmentation (%), 2025
  • Figure 5.1: Prevnar-13 Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 5.2: Gardasil Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 5.3: PENTAct-HIB Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 5.4: Pediarix Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 5.5: Varivax/M-M-R-II/ProQuad Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 5.6: Fluzone/Vaxigrip Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 5.7: Hepatitis Family, GSK: Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 5.8: Zostavax Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 5.9: Pneumovax-23 Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 5.10: RotaTeq Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.1: Human Vaccine Market Shares (%): Top National Markets, 2013
  • Figure 6.2: Developed National Markets: Drivers and Restraints, 2015-2025
  • Figure 6.3: Emerging National Markets: Drivers and Restraints, 2015-2025
  • Figure 6.4: The US Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.5: The Japanese Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.6: The EU Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.7: The German Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.8: The French Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.9: The UK Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.10: The Italian Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.11: The Spanish Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.12: The Brazilian Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.13: The Russian Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.14: The Indian Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 6.15: The Chinese Human Vaccines Revenue Forecast ($bn), 2014-2025
  • Figure 7.1: GSK Vaccines Revenue ($bn), 2012-2013
  • Figure 7.2: GSK Regional Vaccines Breakdown, 2013
  • Figure 7.3: GSK Zoster Vaccines Revenue Forecast ($bn), 2016-2025
  • Figure 7.4: GSK Malaria Vaccines Revenue Forecast ($bn), 2016-2025
  • Figure 7.5: Merck Vaccines Revenue ($bn), 2011-2013
  • Figure 7.6: GSK Malaria Vaccines Revenue Forecast ($bn), 2016-2025
  • Figure 7.7: Sanofi Vaccines Revenue ($bn), 2012-2013
  • Figure 7.8: Sanofi Hexavalent Paediatric Vaccines Revenue Forecast ($bn), 2015-2025
  • Figure 7.9: Sanofi Dengue Fever Vaccines Revenue Forecast ($bn), 2015-2025
  • Figure 7.10: Pfizer Trumenba Vaccines Revenue Forecast ($bn), 2015-2025
  • Figure 7.11: Pfizer C. difficile Vaccines Revenue Forecast ($bn), 2017-2025
  • Figure 7.12: Pfizer S. aureus Vaccines Revenue Forecast ($bn), 2017-2025
  • Figure 7.13: Johnson & Johnson Ebola Vaccines Revenue Forecast ($bn), 2015-2025
  • Figure 7.14: Takeda Dengue Fever Vaccines Revenue Forecast ($bn), 2017-2025
  • Figure 7.15: BiondVax Universal Influenza Vaccines Revenue Forecast ($bn), 2015-2025
  • Figure 8.1: SWOT Analysis of the Human Vaccines Market, 2015
  • Figure 8.2: STEP Analysis of the Human Vaccines Market, 2015
  • Figure 10.1: World Human Vaccines: Regional Market Shares (%), 2025

Companies Listed

  • Aduro Biotech
  • Advisory Committee for Immunization Practices (ACIP)
  • Aspen
  • Astellas
  • Asterias Biotherapeutics
  • AstraZeneca
  • Bavarian Nordic
  • Baxter
  • Bayer
  • Bharat Biotech
  • Bill & Melinda Gates Foundation
  • Binnopharm
  • BiondVax
  • BravoBio
  • Cancer Research UK
  • Center for Biologics Evaluation and Research (CBER)
  • Centers for Disease Control and Protection (CDC)
  • China National Biotec Group
  • China's National Regulatory Authority (CNRA)
  • Chinese Food and Drug Administration (CFDA)
  • Crucell
  • Developing Countries Vaccine Manufacturers Network (DCVMN)
  • Dubai Investments PJSC
  • Eli Lilly
  • European Medicines Agency (EMA)
  • Facebook
  • Food and Drug Administration (FDA)
  • Fresenius
  • GlaxoSmithKline (GSK)
  • Global Alliance for Vaccines and Immunization
  • Globalpharma
  • Health Service Bureau
  • HIV Vaccines Trial Network
  • immatics
  • Indian Department of Biotech
  • InnoPharma
  • Inovio Pharmaceuticals
  • International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
  • International Medica Foundation
  • Inviragen
  • Johnson & Johnson
  • Krka
  • LigoCyte Pharmaceuticals
  • Lupin Pharmaceutical
  • Merck & Co.
  • Ministry of Health, Labour and Welfare
  • NewLink Genetics
  • Novartis
  • Okairos
  • Pan American Health Alliance (PAHO)
  • Pfizer
  • Profectus BioSciences
  • Regulus Therapeutics
  • Roche
  • Rosteh
  • Sanofi
  • Servizio Sanitario Nazionale (SSN)
  • Shanghai BravoBio
  • Shionogi
  • Sistema Único de Saúde (SUS)
  • Takeda
  • UK National Health Service (NHS)
  • Unicef
  • US Department of Health and Human Services (HHS)
  • World Health Organization (WHO)
  • Zymeworks
Show More
Pricing
Back to Top